生物信息学分析CHD3在卵巢癌中的作用

Using Bioinformatics to Analyze the Role of CHD3 in Ovarian Cancer

目的本研究利用生物信息学分析CHD3基因在卵巢癌中的临床作用,探究卵巢癌的潜在肿瘤标志物。方法通过Oncomine数据库检测健康卵巢样品和卵巢癌组织中CHD基因家族的mRNA表达,Kaplan-Meier plotter评估了卵巢癌患者的CHD3的预后值,并利用多种工具分析了与CHD3相关的临床作用,如突变、卵巢癌的临床分期、免疫亚型、药物敏感度和m^(6)A相关基因等。利用R软件对CHD3的GSEA基因富集分析进行了分析。结果卵巢癌患者的CHD3mRNA表达水平显著上调,且高表达CHD3mRNA水平在卵巢癌患者中显示出较好的总生存期和无进展生存期。此外,CHD3的表达水平在免疫亚型等方面比较,差异有统计学意义。CHD3与具有甲基转移酶(METL16、RBM15B)和RNA结合蛋白(YTHDC1)的调节相关基因呈显著正相关,CHD3的表达可考虑确定NSC319726化疗药物在卵巢癌患者中的治疗效果。最后,CHD3可能涉及通过Notch信号通路影响卵巢癌的发展。结论CHD3基因可能是诊断卵巢癌和影响预后的肿瘤标志物。

Objective To investigate the clinical role of CHD3 gene in ovarian cancer and to explore potential tumor markers of ovarian cancer using bioinformatics analysis.Methods We used Oncomine database to detect mRNA expression of CHD gene family in healthy ovarian samples and ovarian cancer tissues,Kaplan-Meier plotter to evaluate the prognosis of CHD3 in ovarian cancer patients,and analyze the clinical effects associated with CHD3,such as mutation,clinical stage of ovarian cancer,immune subtype,drug susceptibility and m^(6) A-related genes.R sofrware was applied to perform the GSEA gene enrichment analysis of CHD3.Results The expression level of CHD3 mRNA in ovarian cancer patients was significantly upregulated,and the high expression level of CHD3 mRNA showed good overall survival and progression-free survival in ovarian cancer patients.In addition,the expression level of CHD3 also varied significantly in terms of immune subtype.CHD3 was significantly and positively correlated with regulation-related genes with methyltransferase(METL16,RBM15B)and RNA-binding protein(YTHDC1),and the expression of CHD3 might be considered to determine the therapeutic effect of NSC319726 chemotherapy drugs in ovarian cancer patients.Finally,CHD3 may be involved in influencing the development of ovarian cancer via the Notch signaling pathway.Conclusion CHD3gene may be a tumor marker for diagnosing ovarian cancer and affecting prognosis.